Bristol-Myers Squibb Company (BMY): Today's Featured Drugs Winner

The drugs industry closed the day down 1.4%. Aoxing Pharmaceutical Company Inc ( AXN), Acura Pharmaceuticals Inc ( ACUR), Medgenics Inc ( MDGN), and YM Biosciences Inc ( YMI) were all winners today within the drugs industry with Bristol-Myers Squibb Company ( BMY) being today's featured drugs winner. Bristol-Myers Squibb Company rose 33 cents (1.1%) to $31.45 on average volume. Throughout the day, 14 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 13.8 million shares.

Bristol-Myers Squibb Company, a global biopharmaceutical company, discovers, develops, and delivers innovative medicines that help patients prevail over serious diseases. Bristol-Myers Squibb Company has a market cap of $52.6 billion and is part of the health care sector. The company has a P/E ratio of 16, below the average drugs industry P/E ratio of 16.1 and below the S&P 500 P/E ratio of 17.7. Shares are up 16.5% year to date as of the close of trading on Thursday.

TheStreet Ratings rates Bristol-Myers Squibb as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, ProPhase Labs Inc ( PRPH), Neptune Technologies & Bioressources Inc ( NEPT), Marina Biotech Inc ( MRNA), and Agenus Inc ( AGEN) were all losers within the drugs industry with Valeant Pharmaceuticals International Inc ( VRX) being today's drugs industry Loser Spotlight stock.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Global Stocks Retreat as U.S.-China Trade War Intensifies

Global Stocks Retreat as U.S.-China Trade War Intensifies

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

Billionaire Investor Tim Draper Explains Why Bitcoin Will Hit $250,000 in 2022

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

To Think a Trade War's Still Just a Threat Is the Dumbest Thing on Wall Street

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

M&A Trends Still on Investors' Minds Despite Worries Over Tariffs -- ICYMI

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods

Dow Falls as U.S. Imposes Tariffs on $50 Billion of Chinese Goods